Ayser Uzala Mızraklı
Research Subjects
Research Interests
Ayser Uzala Mızraklı has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Arzu Rahmanali Onur
UNIVERSITY OF HEALTH SCIENCES, DİYARBAKIR GAZİ YAŞARGİL HEALTH RESEARCH CENTER
2 shared publications - Gülseren Samancı Aktar
Health Sciences University Gazi Yaşargil Training, Turkey
2 shared publications - Ozgur Aslan
Department of Medical Biochemistry, Health Sciences University Diyarbakir Gazi Yasargil Training and Research Hospital,Uçkuyu Mh., 21010, Kayapınar, Diyarbakır, Türkiye
2 shared publications - Ayşe Barış
Hlth Sci Univ, Sisli Hamidiye Etfal Training & Res Hosp, Clin Med Microbiol, Istanbul, Turkiye
1 shared publication - Emrah Gunay
Department of Nephrology, University of Health Sciences, Adana City Training and Research Hospital, 01230 Adana, Turkey
1 shared publication - Enver Yüksel
Division of Nephrology, Department of Internal Medicine, Diyarbakir Gazi Yasargil Training and Research Hospital, University of Health Sciences, Diyarbakir, Turkey
1 shared publication
Latest Publications
- Open Access
- 1 April 2021
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 67 (4) , 597-601
Evaluation of anti-SARS-CoV-2 antibody levels: two different methods
OBJECTIVE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) is still a major problem worldwide. Antibody response to SARS-CoV-2 has not yet been fully clarified, and clinical benefits of serological tests remain unclear. Despite the presence of numerous systems and methods used to analyze antibody levels, it is difficult to mention about standardization. This study aims to evaluate antibody levels of COVID-19 patients obtained by different methods. METHODS: Specimens of 55 patients were included in this study. Patients underwent SARS-CoV-2 real-time polymerase chain reaction test, COVID-19 IgM/IgG antibody rapid test (Hotgen), and Roche SARS-CoV-2 antibody test. RESULTS: In this study, the positive values of COVID-19 IgM/IgG antibody rapid test, Roche SARS-CoV-2 antibody test, and SARS-CoV-2 real-time polymerase chain reaction test were 37, 26, and 31, respectively, whereas the negative values were 18, 29, and 24, respectively. A comparison of the results using.(2) test revealed a significant difference among SARS-CoV-2 real-time polymerase chain reaction, COVID-19 IgM/IgG antibody rapid test (Hotgen), and Roche SARS-CoV-2 antibody test. CONCLUSIONS: We recommend antibody testing in close contact tracing as well as in real-time polymerase chain reaction negative symptomatic subjects. Standardization is important as positive values show significant variations among antibody tests.
- 1 April 2021
- Published by FapUNIFESP (SciELO) in Revista da Associação Médica Brasileira
- Vol. 67 (4) , 597-601
Open AccessEvaluation of anti-SARS-CoV-2 antibody levels: two different methods
OBJECTIVE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) is still a major problem worldwide. Antibody response to SARS-CoV-2 has not yet been fully clarified, and clinical benefits of serological tests remain unclear. Despite the presence of numerous systems and methods used to analyze antibody levels, it is difficult to mention about standardization. This study aims to evaluate antibody levels of COVID-19 patients obtained by different methods. METHODS: Specimens of 55 patients were included in this study. Patients underwent SARS-CoV-2 real-time polymerase chain reaction test, COVID-19 IgM/IgG antibody rapid test (Hotgen), and Roche SARS-CoV-2 antibody test. RESULTS: In this study, the positive values of COVID-19 IgM/IgG antibody rapid test, Roche SARS-CoV-2 antibody test, and SARS-CoV-2 real-time polymerase chain reaction test were 37, 26, and 31, respectively, whereas the negative values were 18, 29, and 24, respectively. A comparison of the results using.(2) test revealed a significant difference among SARS-CoV-2 real-time polymerase chain reaction, COVID-19 IgM/IgG antibody rapid test (Hotgen), and Roche SARS-CoV-2 antibody test. CONCLUSIONS: We recommend antibody testing in close contact tracing as well as in real-time polymerase chain reaction negative symptomatic subjects. Standardization is important as positive values show significant variations among antibody tests.
- Open Access
- 8 February 2021
- Published by Taylor & Francis in Renal Failure
- Vol. 43 (1) , 325-326
A case of peritoneal dialysis in which SARS-CoV-2 was diagnosed by sudden hearing loss
Dear Editor, Sudden hearing loss in cases of SARS-CoV-2 is rare, and it is even less common as a first symptom. For the first time in the literature, we present a case of SARS-CoV-2 accompanied by ...
- 8 February 2021
- Published by Taylor & Francis in Renal Failure
- Vol. 43 (1) , 325-326
Open AccessA case of peritoneal dialysis in which SARS-CoV-2 was diagnosed by sudden hearing loss
Dear Editor, Sudden hearing loss in cases of SARS-CoV-2 is rare, and it is even less common as a first symptom. For the first time in the literature, we present a case of SARS-CoV-2 accompanied by ...
- 2 December 2020
- Published by Galenos Yayinevi in Turkish Journal of Parasitology
- Vol. 44 (4) , 207-210
Retrospective Evaluation of Cases with the Pre-diagnosis of Cystic Echinococcosis Admitted to the Microbiology Laboratory of Diyarbakır Health Sciences Gazi Yaşargil Training and Research Hospital Between 2014 and 2017
Cystic echinococcosis (CE) is a zoonotic disease, which leads to morbidity and mortality worldwide. This study aimed to retrospectively evaluate the presence of anti-Echinococcus granulosus immunoglobulin G (IgG) antibodies, which were detected by indirect fluorescent antibody test in the samples that were transferred to the Microbiology Laboratory of University of Health Sciences Turkey, Diyarbakır Gazi Yaşargil Training and Research Hospital with the pre-diagnosis of CE. Moreover, gender differences with respect to positivity rates of anti-E. granulosus IgG antibodies were investigated. Anti-E. granulosus IgG antibodies, which were detected in the samples of cases with the pre-diagnosis of CE between January 2014 and December 2017, were retrospectively evaluated. Gender difference with respect to positivity rates was investigated by applying the chi-square test in cases with positive anti-E. granulosus IgG antibodies. Out of the 829 serum samples, 222 (26.7%) were found to be positive for E. granulosus IgG antibodies, among which 40 (27.2%), 56 (25.5%), 51 (23.3%) and 75 (30.6%) were found to be positive in 2014, 2015, 2016 and 2017, respectively. No significant difference was found between genders amongst the cases with positive anti-E. granulosus IgG antibodies (p>0.05). Since CE is a major public health problem, evaluation of the presence of anti-E. granulosus IgG antibodies would be important to understand the positivity rate at the regional level.
- 2 December 2020
- Published by Galenos Yayinevi in Turkish Journal of Parasitology
- Vol. 44 (4) , 207-210
Retrospective Evaluation of Cases with the Pre-diagnosis of Cystic Echinococcosis Admitted to the Microbiology Laboratory of Diyarbakır Health Sciences Gazi Yaşargil Training and Research Hospital Between 2014 and 2017
Cystic echinococcosis (CE) is a zoonotic disease, which leads to morbidity and mortality worldwide. This study aimed to retrospectively evaluate the presence of anti-Echinococcus granulosus immunoglobulin G (IgG) antibodies, which were detected by indirect fluorescent antibody test in the samples that were transferred to the Microbiology Laboratory of University of Health Sciences Turkey, Diyarbakır Gazi Yaşargil Training and Research Hospital with the pre-diagnosis of CE. Moreover, gender differences with respect to positivity rates of anti-E. granulosus IgG antibodies were investigated. Anti-E. granulosus IgG antibodies, which were detected in the samples of cases with the pre-diagnosis of CE between January 2014 and December 2017, were retrospectively evaluated. Gender difference with respect to positivity rates was investigated by applying the chi-square test in cases with positive anti-E. granulosus IgG antibodies. Out of the 829 serum samples, 222 (26.7%) were found to be positive for E. granulosus IgG antibodies, among which 40 (27.2%), 56 (25.5%), 51 (23.3%) and 75 (30.6%) were found to be positive in 2014, 2015, 2016 and 2017, respectively. No significant difference was found between genders amongst the cases with positive anti-E. granulosus IgG antibodies (p>0.05). Since CE is a major public health problem, evaluation of the presence of anti-E. granulosus IgG antibodies would be important to understand the positivity rate at the regional level.
- 1 August 2019
- Published by Galenos Yayinevi in Viral Hepatitis Journal
- Vol. 25 (2) , 62-66
Genotyping Distribution of Hepatitis C Virus in Şanlıurfa Province and Effect of Syrian Patients
- 1 August 2019
- Published by Galenos Yayinevi in Viral Hepatitis Journal
- Vol. 25 (2) , 62-66
Genotyping Distribution of Hepatitis C Virus in Şanlıurfa Province and Effect of Syrian Patients